Another important piece of information regarding normal tissue toxicity when bypassing ABCG2 concerns studies where cancer patients have received novel types of topoisomerase inhibitors that are not substrates for ABCG2 [68,69,70]. The gene discussed is ABCG2; the disease is cancer.